Dydrogesterone tablet

According to a community-based cross-sectional study on the prevalence of primary infertility and its associated risk factors in urban population of Central India by A Katole, a quarter of women who suffer from infertility in the world, between 15 to 20 million, reside in India. Quoting the research published in the Journal of Obstetrics and Gynecology of India, Dr Nandita Palshetkar, president of FOGSI (Federation of Obstetrics and Gynecological Society of India) observed that 10-15 per cent of clinically recognised pregnancies worldwide end in a miscarriage and Indian women have a higher prevalence of miscarriage—as high as 32 per cent. Addressing the media on Thursday afternoon, Dr Palshetkar said, "Given rapid urbanization and the shift in cultural dynamics, maternal age in India is advancing. Moreover, an increase in the number of miscarriages can lead to an increase in the likelihood of subsequent miscarriages to 13-17 per cent after the first miscarriage and 55 per cent after the third miscarriage. This underscores the need for medicines and treatments that ensure healthy pregnancies." Also read • • • • Accordingly, she suggested Oral Dydrogesterone as one of the solutions to the problem, saying that "it helps improve pregnancy outcomes as it is a potent treatment for prevention of miscarriage during the first trimester and for luteal phase support during in-vitro fertilization (IVF)." Her opinion was seconded by Sieneke Bult-Muntinga, site director, Abbott Netherla...

Dysmenorrhoea, endometriosis, secondary amenorrhoea, irregular cycles, dysfunctional uterine bleeding, pre-menstrual syndrome, threatened & habitual abortion associated w/ proven progesterone deficiency, infertility due to luteal insufficiency, HRT. Luteal support as part of assisted reproductive technology (ART) treatment. Dysmenorrhoea 1 tab bd from day 5-25 of cycle. Endometriosis 1 tab bd-tds from day 5-25 of cycle or continuously. Dysfunctional bleeding (to stop bleeding) 1 tab bd for 5-7 days, (to prevent bleeding) 1 tab bd from day 11-25 of cycle. Amenorrhoea 1 tab bd from day 11-25 of cycle w/ oestrogen once daily from day 1-25 of cycle. Premenstrual syndrome/irregular cycles 1 tab bd from day 11-25 of cycle. Threatened abortion 4 tab at once, then 1 tab every 8 hr until reduced symptoms. Habitual abortion 1 tab bd until 20th wk of pregnancy. Infertility due to luteal insufficiency 1 tab daily from day 14-25 of cycle for at least 6 consecutive cycles. Luteal support as part of ART treatment 1 tab tds starting at oocyte retrieval day & continue for 10 wk in confirmed pregnancy. HRT In combination w/ continuous oestrogen therapy: 1 tab daily for 14 consecutive days of 28-day cycle. In combination w/ cyclical oestrogen therapy: 1 tab daily during last 12-14 days of oestrogen therapy. Discontinue use if VTE develops. Determine bleeding etiology prior to treatment. Increased risk of endometrial hyperplasia & carcinoma; breast & ovarian cancer. Porphyria, depression, abn...

• • • Sexual Health • • • • • • • Women Health • • • • • • • Skin Issues • • • • Hair Problem • • • • • Chronic • • • • • • • • • • • • • • Disease • Sexual Health • Podcast • Hospital Directory • Doctor Directory • Health T.V. • Web Stories • • Treatments • • • • • • • • • • Yoga And Fitness • • • • • • Women • • • • • • Other Topics • • • • • • • • • Carbamazepine • • • • Phenobarbital • • • • Rifampicin • • • • Phenytoin • • • • Dydrogesterone Contraindications If you are suffering from any of the following diseases, you should not take Dydrogesterone unless your doctor advises you to do so - • Coronary Artery Disease (CAD) • Liver Disease • Miscarriage • Breast Cancer Frequently asked Questions about Dydrogesterone MBBS , General Physician Dydrogesterone is a synthetic progestin hormone. It is used to treat irregular menstrual cycles resulting from the progesterone deficiency. It is also used for preventing abortions in females who have a history of natural abortions (miscarriage). It is used for the management of estrogen deficiency in pre and post-menopausal women. Disclaimer: All information and articles available on this site are for educational purposes only. The information given here should not be used without any expert advice for the diagnosis or treatment of any health related problem or disease. Always seek the advice of a qualified doctor for medical examination and treatment. © 2023, myUpchar. All Rights Reserved

FEMOSTON ® (Estradiol & Dydrogesterone) Indications for 1/10 mg: • Sequential combined is indicated for Oestrogen deficiency in postmenopausal women 6 months or more after last menstruation • Indications for 1/5 mg: • Indicated for oestrogen deficiency symptoms in postmenopausal women 12 months or more after last menstruation Available Dosage: • 28 Tablets 1/5 mg • 28 Tablets 1/10 mg © 2022 Abbott. All Rights Reserved. Please read the Legal Notice for further details. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

Femoston-conti tablets are a type of What is Femoston-conti used for? It is a type of hormone replacement therapy (HRT), used to relieve symptoms of the menopause. It can be used as a second-line option for preventing osteoporosis in postmenopausal women who are at high risk of fractures and cannot take other medicines licensed for preventing osteoporosis (Femoston-conti 1mg/5mg only). In December 2003, a review of the available evidence on the risks and benefits of HRT by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Committee on Safety of Medicines (CSM) in the UK, concluded that the risks of using HRT long-term to prevent osteoporosis in women aged over 50 years exceed the benefits. As a result this medicine should not be used as a first-line option for preventing postmenopausal Women considered to be at risk of developing fractures following the menopause include those who have had an early menopause, those with a family history of osteoporosis, those who have had recent prolonged corticosteroid therapy (eg prednisolone), those with a small thin frame, and smokers. You can read more about the risks and benefits of HRT and other medicines for preventing osteoporosis in the factsheets about menopause and osteoporosis linked above. Hormone replacement therapy explained How does Femoston-conti work? Femoston-conti tablets contain two active ingredients, estradiol (previously spelt oestradiol in the UK) and dydrogesterone. These are forms of the mai...

Medical uses [ ] Dydrogesterone has proven effective in a variety of conditions associated with progesterone deficiency, Gynecological disorders [ ] Primary or essential dysmenorrhea is a very common gynecological phenomenon experienced by women during their reproductive years. Clinical studies have shown symptom relief and a reduction in pain with dydrogesterone treatment for dysmenorrhea. Endometriosis is a chronic disease which can cause severe, progressive, and at times, incapacitating dysmenorrhea, Dydrogesterone has shown reasonable efficacy in relieving a number of premenstrual syndrome symptoms like Infertility and miscarriage [ ] Oral dydrogesterone is an effective medication, well tolerated and accepted among patients, and can be considered for routine Threatened Hormone therapy [ ] The objective behind Estrogen promotes endometrial cell growth and in Available forms [ ] • v • t • e Risk of breast cancer with menopausal hormone therapy in large observational studies (Mirkin, 2018) Study Therapy CI) E3N-EPIC: Fournier et al. (2005) Estrogen alone 1.1 (0.8–1.6) Estrogen plus Transdermal estrogen Oral estrogen 0.9 (0.7–1.2) 0.9 (0.7–1.2) No events Estrogen plus progestin Transdermal estrogen Oral estrogen 1.4 (1.2–1.7) 1.4 (1.2–1.7) 1.5 (1.1–1.9) E3N-EPIC: Fournier et al. (2008) Oral estrogen alone 1.32 (0.76–2.29) Oral estrogen plus progestogen Dydrogesterone Not analyzed a 0.77 (0.36–1.62) 2.74 (1.42–5.29) 2.02 (1.00–4.06) 2.57 (1.81–3.65) 1.62 (0.94–2.82) 1.10 (0...